Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on May 27, 2022 10:10am
163 Views
Post# 34711888

RE:RE:Cedars Sinai has now started recruiting!

RE:RE:Cedars Sinai has now started recruiting!So, it appears that both Mary Crowley and Cedars Sinai are up and running now. Clinicaltrials.gov still do not acknowledge that but that is not surprising as the website is typically updated only sporadically. Now, we need to see some additional centers added to the list and we shoiu,d also see some European cancer test sites open but likely not until July as it takes longer to get going there.

I find it interesting how Crowley and Cedars Sinai describe the cancers they are looking at in the TH-1902 trial as it seems much broader than what TH has said. Are the cancers they note on their websites just subsets of the cancers TH said the phase 1b will test?   

scarlet1967 wrote: The professor in charge...

“Specialty

  • IM/Hematology/Oncology

Research Profile

The research of Monica Mita, MD, focuses on the phase I clinical trials in oncology, novel drugs and targeted therapies.

Education

  • Medical School: Carol Davila University, Romania, 1992
  • Fellowship: University of Texas Health Science Center, 2005
  • Fellowship: Cancer Therapy and Research Center, 2006”

 

https://bio.cedars-sinai.org/mitam/index.html



<< Previous
Bullboard Posts
Next >>